Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Todos Medical Ltd.
  6. News
  7. Summary
    TOMDF   IL0011392375

TODOS MEDICAL LTD.

(TOMDF)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

TODOS MEDICAL LTD. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)

04/14/2021 | 03:06pm EDT

Item 1.01 Entry into a Material Definitive Agreement.

On April 8, 2021, Todos Medical Ltd. (the "Company") entered into a Securities Purchase Agreement (the "SPA") with an institutional investor (the "Purchaser") pursuant to which the Company has agreed to issue a promissory convertible note (the "Note") to the Purchaser in the principal amount of $4,285,714.29 for proceeds of $3,000,000 (the "Transaction"). The closing occurred on April 12, 2021 (the "Closing Date"). The Note has a maturity date of one year from the date of issuance and pays interest at a rate of 4% per annum. The Note is convertible into shares of Common Stock (the "Conversion Shares") at a conversion price of $0.0599 (the "Conversion Price). In addition, the Purchaser received a warrant (the "Warrant") to purchase up to 16,000,000 shares of Common Stock (the "Warrant Shares") of the Company with an exercise price equal to $0.107415 per share. The Warrant is exercisable for 5 years from the date of issuance. From the Closing Date until 180 days thereafter, the Company shall be restricted from issuing or entering into any agreement to issue any shares of Common Stock, except under certain circumstances. This provision shall no longer be in effect if the closing sale price of the Common Stock exceeds $0.10. The Company intends to use the net proceeds from this Note to initiate the Phase 2 for Tollovir™ clinical trial in COVID-19 patients, complete the acquisition of Provista Diagnostics, Inc. and for general corporate purposes.

The Company has agreed to file a registration statement with the Securities and Exchange Commission registering for resale the Conversion Shares and the Warrant Shares (the "Registration Statement). Subsequent to the effective date of such registration statement, if the closing sale price of the Common Stock averages less than the then Conversion Price over a period of ten (10) consecutive trading days, the Conversion Price shall reset to such average price. If the 10 day volume weighted average price of the Common Stock continues to be less than the Conversion Price then the Conversion Price should reset to such 10-day average price with a maximum of a 20% discount from the initial Conversion Price.

The Purchaser has the option to purchase an additional Note in the principal amount of $5,285,714.20 for proceeds of $3,700,000 and an additional Warrant to purchase 16,000,000 shares of Common Stock.

The foregoing descriptions of the SPA, the Note and the Warrant do not purport to be complete and are qualified in their entirety by reference to the full text of the SPA, Note and Warrant, forms of which are attached as Exhibit 10.1, 10.2 and 10.3, respectively, to this Current Report on Form 8-K, and are incorporated herein by reference.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information included in Item 1.01 of this Form 8-K is hereby incorporated by reference into this Item 2.03.

Item 3.02 Unregistered Sales of Equity Securities.

The information included in Item 1.01 of this Form 8-K is hereby incorporated by reference into this Item 3.02.

The issuance of the securities described in item 1.01 was deemed to be exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), by virtue of Section 4(a)(2) and Rule 506 promulgated thereunder.

Item 9.01. Financial Statements and Exhibits




(d) Exhibits.



10.1     Securities Purchase Agreement dated April 8, 2021.
10.2     Form of Promissory Convertible Note.
10.3     Form of Warrant.




-2-

© Edgar Online, source Glimpses

All news about TODOS MEDICAL LTD.
06/22TODOS MEDICALá : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
AQ
05/04TODOS MEDICAL LTD.á : Other Events (form 8-K)
AQ
05/04TODOS MEDICALá : Receives FDA Certificate of Free Sale for New 5-Day Tollovid Do..
AQ
04/30TODOS MEDICAL LTD.á : Entry into a Material Definitive Agreement, Creation of a ..
AQ
04/23TODOS MEDICAL LTD.á : Entry into a Material Definitive Agreement, Completion of ..
AQ
04/22Todos Medical Acquires Provista Diagnostics and Its Proprietary Videssa Breas..
GL
04/21TODOS MEDICALá : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
AQ
04/19Todos Medical Launches Phase 2 Clinical Trial of Its Antiviral 3CL Protease I..
GL
04/14TODOS MEDICAL LTD.á : Entry into a Material Definitive Agreement, Creation of a ..
AQ
04/08Todos Medical Receives Notice of Allowance from European Patent Office for Pa..
GL
More news
Financials (USD)
Sales 2020 5,21  - -
Net income 2020 -29,8 M - -
Net Debt 2020 10,5 M - -
P/E ratio 2020 -0,65x
Yield 2020 -
Capitalization 26,4 M 26,4 M -
EV / Sales 2019 -
EV / Sales 2020 7 726 750x
Nbr of Employees 7
Free-Float 73,5%
Chart TODOS MEDICAL LTD.
Duration : Period :
Todos Medical Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Gerald E. Commissiong President, Chief Executive Officer & Director
Daniel Hirsch Chief Financial Officer & Director
Herman Weiss Chairman
Elise Brownell Vice President-Research & Development
Jorge Leon Chief Medical & Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
TODOS MEDICAL LTD.-41.47%26
EXACT SCIENCES CORPORATION-3.43%21 948
GUARDANT HEALTH, INC.-4.24%12 480
BGI GENOMICS CO., LTD.-7.47%7 469
INVITAE CORPORATION-20.78%6 619
ADAPTIVE BIOTECHNOLOGIES CORPORATION-32.86%5 570